Table 1 Patient and specimen characteristics
From: Targeted mutation detection in breast cancer using MammaSeq™
Patients with available tumor tissue (n = 46) | Patients with available blood samples (n = 7) | |
|---|---|---|
Age | ||
Median age (years) | 45 | 53 |
Range (years) | 31–71 | 24–62 |
Race | ||
White | 45 (97.8%) | 7 (100.0%) |
Black | 1 (2.2%) | 0 (0.0%) |
Site | ||
Primary | 10 (21.7%) | 0 (0.0%) |
Metastatic | 36 (78.3%) | 7 (100.0%) |
Stage (Dx) | ||
I | 10 (21.7%) | 0 (0.0%) |
II | 8 (17.4%) | 3 (21.4%) |
III | 13 (28.3%) | 0 (0.0%) |
IV | 4 (8.7%) | 2 (14.3%) |
Unknown | 11 (23.9%) | 2 (14.3) |
Hormone-receptor | ||
HR+ and HER2– | 19 (41.3%) | 2 (28.6%) |
HR+ and HER2+ | 5 (10.9%) | 0 (0.0%) |
HR+ and HER2 unknown | 1 (2.2%) | 0 (0.0%) |
HR– and HER2+ | 1 (2.2%) | 0 (0.0%) |
HR– and HER2– | 17 (36.9%) | 0 (0.0%) |
Both unknown | 2 (4.3%) | 5 (71.4%) |
Histopathology | ||
Ductal | 34 (73.9%) | 7 (100%) |
Lobular | 5 (10.9%) | 0 (0.0%) |
Mixed | 3 (6.5%%) | 0 (0.0%) |
Other/unknown | 4 (8.7%) | 0 (0.0%) |